Development of Blood Delivery Networks for Silicon Nanomembrane-Enabled Low-Volume Membrane Oxygenators

Information

  • Research Project
  • 10111004
  • ApplicationId
    10111004
  • Core Project Number
    R21HL156143
  • Full Project Number
    1R21HL156143-01
  • Serial Number
    156143
  • FOA Number
    PA-19-053
  • Sub Project Id
  • Project Start Date
    1/1/2021 - 3 years ago
  • Project End Date
    12/31/2022 - a year ago
  • Program Officer Name
    NATARAJAN, ARUNA R
  • Budget Start Date
    1/1/2021 - 3 years ago
  • Budget End Date
    12/31/2021 - 2 years ago
  • Fiscal Year
    2021
  • Support Year
    01
  • Suffix
  • Award Notice Date
    12/31/2020 - 3 years ago

Development of Blood Delivery Networks for Silicon Nanomembrane-Enabled Low-Volume Membrane Oxygenators

Abstract The overall goal of this project is to optimize performance and hemocompatibility of prototype blood oxygenators enabled by silicon nanomembranes. To achieve this, the project brings together expertise in blood-contacting medical device hemodynamics (Co-PI Steven Day; Chair and Prof. Biomedical Engi- neering, Rochester Institute of Technology) with silicon nanomembrane production at SiMPore Inc. (Co-PI James Roussie). Together, SiMPore and RIT offer a high impact and innovative approach for pro- ducing device geometries and material systems. SiMPore?s nanomembranes offer orders-of-magnitude higher permeability than polymer membranes used in current ECMO oxygenators and compelling pre- liminary data are demonstrative of these advantages. Since the overall volume of an oxygenator is de- pendent on the surface area and permeability of its membranes, incorporating SiMPore?s highly perme- able silicon nanomembranes into an efficient blood delivery and gas exchange system will lead to scaled down circuit blood volumes and dramatically lower surface areas of blood exposure. Leveraging Co-PI Day?s expertise in modeling and testing of hemolytic and thrombogenic potential of blood-con- tacting medical devices, a blood delivery network will be iteratively designed in silico and tested with installed nanomembranes in vitro so that the full permeability of nanomembrane-based oxygenation is realized within a safe and efficient device geometry. Aim 1 will focus on iterative in silico prototype oxy- genator design and initial empirical performance characterization, while Aim 2 will focus on a perfected design?s hemocompatibility and comparative performance versus currently in-use polypropylene mem- brane oxygenators. Success out of this R21 project will lay the basis for testing of the nanomembrane- based oxygenator in animal models.

IC Name
NATIONAL HEART, LUNG, AND BLOOD INSTITUTE
  • Activity
    R21
  • Administering IC
    HL
  • Application Type
    1
  • Direct Cost Amount
    209430
  • Indirect Cost Amount
    52975
  • Total Cost
    262405
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    838
  • Ed Inst. Type
    BIOMED ENGR/COL ENGR/ENGR STA
  • Funding ICs
    NHLBI:262405\
  • Funding Mechanism
    Non-SBIR/STTR RPGs
  • Study Section
    BTSS
  • Study Section Name
    Bioengineering, Technology and Surgical Sciences Study Section
  • Organization Name
    ROCHESTER INSTITUTE OF TECHNOLOGY
  • Organization Department
    BIOMEDICAL ENGINEERING
  • Organization DUNS
    002223642
  • Organization City
    ROCHESTER
  • Organization State
    NY
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    146235608
  • Organization District
    UNITED STATES